Joris L Vos, Bharat Burman, Swati Jain, Conall W R Fitzgerald, Eric J Sherman, Lara A Dunn, James V Fetten, Loren S Michel, Anuja Kriplani, Kenneth K Ng, Juliana Eng, Vatche Tchekmedyian, Sofia Haque, Nora Katabi, Fengshen Kuo, Catherine Y Han, Zaineb Nadeem, Wei Yang, Vladimir Makarov, Raghvendra M Srivastava, Irina Ostrovnaya, Manu Prasad, Charlotte L Zuur, Nadeem Riaz, David G Pfister, Christopher A Klebanoff, Timothy A Chan, Alan L Ho, Luc G T Morris
Salivary gland cancers (SGCs) are rare, aggressive cancers without effective treatments when metastasized. We conducted a phase 2 trial evaluating nivolumab (nivo, anti-PD-1) and ipilimumab (ipi, anti-CTLA-4) in 64 patients with metastatic SGC enrolled in two histology-based cohorts (32 patients each): adenoid cystic carcinoma (ACC; cohort 1) and other SGCs (cohort 2). The primary efficacy endpoint (≥4 objective responses) was met in cohort 2 (5/32, 16%) but not in cohort 1 (2/32, 6%). Treatment safety/tolerability and progression-free survival (PFS) were secondary endpoints...
August 24, 2023: Nature Medicine